A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

Inclusion Criteria:

- Are ambulatory.

- Diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA) and fulfilling the
2009 ASAS classification criteria.

- Have a history of back pain ≥3 months with age at onset <45 years.

- Have active nr-axSpA defined as BASDAI ≥4 and total back pain ≥4 on a NRS at screening
and baseline.

- Have objective signs of inflammation by presence of sacroiliitis on MRI and/or
presence of elevated CRP.

- In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.

- If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.

- Have a history of prior therapy for axSpA for at least 12 weeks prior to screening.

Exclusion Criteria:

- Have radiographic sacroiliitis fulfilling the 1984 modified New York criteria.

- Have received any prior, or are currently receiving treatment with biologics, tumor
necrosis factor inhibitors or other immunomodulatory agents.

- Have received a live vaccine within 12 weeks or have had a vaccination with Bacillus
Calmette-Guerin (BCG) within the past year.

- Have an ongoing or serious infection within the last 12 weeks or evidence of active
tuberculosis.

- Have a compromised immune system.

- Have any other serious and/or uncontrolled diseases.

- Have either a current diagnosis or a recent history of malignant disease.

- Have had major surgery within 8 weeks of baseline, or will require surgery during the
study.

- Are pregnant or breastfeeding.

- Have evidence of active anterior uveitis (an acute episode) within the last 42 days
prior to baseline randomization.